Pronóstico del mercado de servicios de farmacocinética en Oriente Medio y África hasta 2031: análisis regional, por tipo de fármaco (moléculas pequeñas, moléculas grandes y vacunas), tipo de servicio (estudios preclínicos de ADME y humanos, análisis y generación de informes de PK/PD, simulaciones de dosificación, análisis de riesgos y otros), aplicación terapéutica (oncología, enfermedades infecciosas, trastornos neurológicos, enfermedades autoinmunes, trastornos ginecológicos, enfermedades cardiovasculares, trastornos respiratorios y otros) y usuario final (empresas farmacéuticas y de biotecnología, organizaciones de investigación por contrato y otros)
La creciente prevalencia de enfermedades crónicas e infecciosas impulsa el mercado de servicios farmacocinéticos de Oriente Medio y África
La creciente prevalencia de enfermedades crónicas como la diabetes, el cáncer y las enfermedades autoinmunes ha sido un factor fundamental en los esfuerzos de desarrollo de fármacos en todo el mundo. Según los datos de 2024 de la Organización Mundial de la Salud (OMS), aproximadamente 422 millones de personas en el mundo padecen diabetes, y estos casos se encuentran principalmente en países de ingresos medios y bajos, lo que causa aproximadamente 1,5 millones de muertes cada año. Las empresas farmacéuticas están a la vanguardia del desarrollo de medicamentos para tratar diversas enfermedades. Los estudios farmacocinéticos son esenciales para comprender cómo se comportan estos fármacos en el cuerpo de un paciente mediante el análisis del proceso de absorción, distribución, metabolización y eliminación (ADME) dentro del cuerpo humano. La absorción de un fármaco en la circulación sistémica afecta la velocidad y la concentración a la que un fármaco puede llegar al sitio de acción, por ejemplo, el plasma. Los patrones de distribución de fármacos en todo el cuerpo varían según sus propiedades bioquímicas y la fisiología corporal. El metabolismo implica el procesamiento del fármaco por parte del cuerpo en compuestos posteriores. Este paso es fundamental para convertir el fármaco en sustancias solubles en agua para que sean adecuadas para la depuración renal. El metabolismo también es importante para la conversión de profármacos, como la codeína, en metabolitos activos. La excreción de fármacos del cuerpo está gobernada principalmente por los riñones; sin embargo, en varios casos, los fármacos pueden excretarse a través de los pulmones, la piel o el tracto gastrointestinal. La dinámica de ADME define la biodisponibilidad de los fármacos en el cuerpo, y las dosis de mantenimiento de los fármacos se calculan en función de sus tiempos de depuración (concentración plasmática deseada dividida por la biodisponibilidad). La comprensión de la autorización permite a los médicos calcular las dosis adecuadas.
Los estudios farmacocinéticos se centran en optimizar los regímenes de dosis de los fármacos en los sujetos del estudio para comprender la eficacia y la seguridad de un fármaco. Estos estudios son esenciales para garantizar la seguridad de los fármacos que se desarrollan para tratamientos a largo plazo, lo que ayuda a evaluar la idoneidad y la estabilidad de las formulaciones de los fármacos en el tratamiento de enfermedades crónicas. Por lo tanto, la creciente carga de enfermedades crónicas e infecciosas subraya la importancia de los estudios farmacocinéticos para desarrollar tratamientos personalizados seguros y eficaces.
Resumen del mercado de servicios farmacocinéticos de Oriente Medio y África
Sudáfrica representa la mayor parte del mercado de servicios farmacocinéticos en Oriente Medio y África. El gobierno de Sudáfrica ha comenzado a proporcionar incentivos a la inversión, a tomar medidas para proteger los derechos de propiedad intelectual (PI), a simplificar las normas fiscales y a aplicar mejores políticas regulatorias para atraer inversiones extranjeras y, en última instancia, nutrir el panorama de los ensayos clínicos en el país. En 2019, se invirtió un total de ~US$ 62,67 millones (ZAR 1 mil millones) en ensayos futuros y en curso. Durante el período 2016-2021, las empresas farmacéuticas multinacionales innovadoras que operan en Sudáfrica gastaron aproximadamente 0,18 mil millones de dólares estadounidenses (2,95 mil millones de rands) para apoyar las actividades de investigación clínica centradas en abordar las necesidades médicas no satisfechas del país.
Sudáfrica es el país económicamente más desarrollado del continente africano y ha establecido mejores estándares regulatorios para los ensayos clínicos. Los menores costos de las operaciones de investigación clínica y un menor riesgo de litigio hacen de Sudáfrica una opción atractiva para las empresas extranjeras que subcontratan sus operaciones de investigación clínica. Además, el número de ensayos ha aumentado debido a las altas tasas de reclutamiento y a un entorno regulatorio mejorado en el país. Sudáfrica recibe patrocinios sustanciales de empresas farmacéuticas innovadoras para realizar investigaciones clínicas, y no hay señales de desaceleración. Por lo tanto, el progreso de la industria de la investigación clínica impulsa el crecimiento del mercado de servicios farmacocinéticos en el país.
Ingresos y pronóstico del mercado de servicios farmacocinéticos de Oriente Medio y África hasta 2031 (millones de USD)
Segmentación del mercado de servicios farmacocinéticos de Oriente Medio y África
El mercado de servicios farmacocinéticos de Oriente Medio y África se clasifica en tipo de fármaco, tipo de servicio, aplicación terapéutica, usuario final y país.
Según el tipo de fármaco, el mercado de servicios farmacocinéticos de Oriente Medio y África se segmenta en moléculas pequeñas, moléculas grandes y vacunas. El segmento de moléculas pequeñas tuvo la mayor participación de mercado en 2023.
En términos de tipo de servicio, el mercado de servicios farmacocinéticos de Oriente Medio y África se clasifica en estudios preclínicos ADME y humanos, análisis e informes PK/PD, simulaciones de dosificación, análisis de riesgos y otros. El segmento de estudios preclínicos en humanos y ADME tuvo la mayor participación de mercado en 2023.
Por aplicación terapéutica, el mercado de servicios farmacocinéticos de Oriente Medio y África está segmentado en oncología, enfermedades infecciosas, trastornos neurológicos, enfermedades autoinmunes, trastornos ginecológicos, enfermedades cardiovasculares, trastornos respiratorios y otros. El segmento de oncología tuvo la mayor participación de mercado en 2023.
Por usuario final, el mercado de servicios farmacocinéticos de Oriente Medio y África está segmentado en empresas farmacéuticas y biotecnológicas, organizaciones de investigación por contrato y otros. El segmento de organizaciones de investigación por contrato tuvo la mayor participación de mercado en 2023.
Por país, el mercado de servicios farmacocinéticos de Oriente Medio y África está segmentado en Sudáfrica, Arabia Saudita, los Emiratos Árabes Unidos y el resto de Oriente Medio y África. Sudáfrica dominó la participación de mercado de servicios farmacocinéticos de Oriente Medio y África en 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; y SGS SA se encuentran entre las empresas líderes que operan en el mercado de servicios farmacocinéticos de Medio Oriente y África.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Middle East & Africa Analysis
5.1 Middle East & Africa Pharmacokinetics Services Market Overview
5.2 Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Middle East & Africa Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Middle East & Africa Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Middle East & Africa Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Middle East & Africa Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Middle East & Africa Pharmacokinetics Services Market - Country Analysis
10.1 Middle East and Africa
10.1.1 Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Middle East & Africa Pharmacokinetics Services Market Segmentation
Table 2. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 3. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 4. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 5. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 6. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 7. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 8. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 9. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 10. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 11. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 12. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 13. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 14. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Drug Type
Table 15. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Service Type
Table 16. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by Therapeutic Application
Table 17. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) - by End User
Table 18. Glossary of Terms
?
List of Figures
Figure 1. Middle East & Africa Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Middle East & Africa Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Middle East & Africa Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Middle East & Africa Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Middle East & Africa Pharmacokinetics Services Market by Key Countries - Revenue 2023 (US$ Million)
Figure 29. Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 31. South Africa: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 32. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 33. Rest of Middle East & Africa Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Middle East & Africa pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.